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The effect of statins on all-cause mortality in the general population has been estimated as
0.86 (95%CI 0.79-0.94) for primary prevention. Reported values in HIV-infected individuals
have been discordant. We assessed the impact of statin-based primary prevention on all-
cause mortality among HIV-infected individuals.
Methods
Patients were selected among controls from a multicentre nested case-control study on the
risk of myocardial infarction. Patients with prior cardiovascular or cerebrovascular disorders
were not eligible. Potential confounders, including variables that were associated either
with statin use and/or death occurrence and statin use were evaluated within the last 3
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months prior to inclusion in the case-control study. Using an intention to continue approach,
multiple imputation of missing data, Cox’s proportional hazard models or propensity based
weighting, the impact of statins on the 7-year all-cause mortality was evaluated.
Results
Among 1,776 HIV-infected individuals, 138 (8%) were statins users. During a median fol-
low-up of 53 months, 76 deaths occurred, including 6 in statin users. Statin users had more
cardiovascular risk factors and a lower CD4 T cell nadir than statin non-users. In univariable
analysis, the death rate was higher in statins users (11% vs 7%, HR 1.22, 95%CI 0.53-
2.82). The confounders accounted for were age, HIV transmission group, current CD4 T
cell count, haemoglobin level, body mass index, smoking status, anti-HCV antibodies posi-
tivity, HBs antigen positivity, diabetes and hypertension. In the Cox multivariable model the
estimated hazard ratio of statin on all-cause mortality was estimated as 0.86 (95%CI 0.34-
2.19) and it was 0.83 (95%CI 0.51-1.35) using inverse probability treatment weights.
Conclusion
The impact of statin for primary prevention appears similar in HIV-infected individuals and in
the general population.
Introduction
Human immunodeficiency virus (HIV) infection induces chronic inflammation and immune
activation, even during effective antiretroviral therapy (ART) [1]. Some markers of inflamma-
tion are associated with adverse cardiovascular outcomes in both HIV-infected and uninfected
populations [2,3]. Statins are widely used for primary prevention of atherosclerotic cardiovas-
cular disease and are known to decrease cholesterol level as well as inflammation. In the JUPI-
TER trial [4], involving apparently healthy men aged 50 years or more and women aged 60
years or more without hyperlipidaemia but with elevated high-sensitivity C-reactive protein
(CRP) levels, rosuvastatin significantly reduced all-cause mortality (hazard ratio [HR] 0.80,
95% confidence interval [CI] 0.67–0.97), and the most recently published meta-analysis
unequivocally supports statin-based primary prevention [5], with an odds ratio (OR) of 0.86
(95%CI 0.79–0.94) [5]. The effect of statins use on overall mortality in HIV-infected individu-
als remains controversial [6–9], probably because potential confounders were not adequately
taken into account in some studies. In a study a far more potent effect has even been reported
in HIV-infected individuals [6] than in the general population [5] without discussion about
why. We therefore examined the effect of statin-based primary prevention on all-cause mortal-
ity in HIV-infected individuals, by comparison with the general population without prior myo-
cardial infarction or stroke.
Study population and methods
The patients selected for this study were the controls from a case-control study of myocardial
infarction (MI) [10], nested within the French Hospital Database on HIV (FHDH-ANRS
CO4), an ongoing, prospective, observational, nationwide, hospital-based cohort of HIV-
infected individuals [11]. Enrolments took place from January 2000 through December 2009.
Patients with prior cardiovascular or cerebrovascular disorders were not eligible. The outcome
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measure was all-cause mortality, censored at 7 years of follow-up. Individuals were considered
to be statin users if a statin had been prescribed within 3 months prior to the index date,
defined as the date of MI in the corresponding case. Patients were followed from the index date
until 7 years, or the last follow-up, or death, whichever occurred first. An intention-to-continue
approach was used to mimic what would happen in a clinical trial. To include all patients in
the analyses, missing values of potential confounders were imputed as previously described
[12]. Cases with prior exposure to statin were also corresponding to the definition of statin use
for primary prevention, and therefore removing them could lead to a selection bias. However,
including all of them would also bias the result by over representing people with MI in our
dataset. From January 2000 through December 2009, 96,091 HIV-infected individuals were fol-
lowed in the FHDH ANRS CO4 cohort. During the same period, 600 HIV-infected individuals
had a first validated myocardial infarction, among which 95 patients were on statin therapy,
that is 95/96,091; roughly 1/1000. Therefore, to be representative, we should have add around
two cases to our study population. In a sensitivity analysis, we randomly selected two of these
95 patients, 10 times, to include them in the analysis. The results of these 10 analyses were com-
bined using Rubin’s rules [12].
The first step of the analysis was to select, among the different ways of modelling continuous
variables (as continuous variables, after log transformation, or as categorical variables defined
by tertiles), the approach yielding the lowest value of Akaike’s univariable information criterion
in Cox models of the risk of death (outcome variable). Then, potential confounders linked either
to the risk of death (using Cox models) or to statin use (using logistic regression) were selected.
The tested variables were age, gender, HIV transmission group, current CD4 and CD8 T cell
counts, CD4 T cell nadir, CD4/CD8 T cell ratio, CD4 T cell nadir/CD8 T cell ratio, plasma
HIV-1 RNA level, AIDS status, the haemoglobin level, body mass index (BMI), smoking status,
hypertension or use of antihypertensive treatment, diabetes or use of antidiabetic treatment,
anti-HCV antibodies and HBs antigen status, non-AIDS malignancy (CIM-10 definition), liver
failure, chronic kidney disease, cirrhosis, and pulmonary embolism. For parameters that
changed over time, the latest measurement available within 3 months prior to the index date
was used. Cholesterol level, which is influenced by statin use, was not considered as a potential
confounder but as a consequence of exposure, which could have started many years before, and
therefore, as recommended, no adjustment was made on cholesterol level. Variables linked to
the risk of death and/or to the risk of statin use were then entered in two stepwise multivariable
models, one on the risk of death and the other on statin use, and variables with p values below
0.10 in at least one of the models were retained. Finally, to examine the association of statin use
with the occurrence of death, a Cox regression model was constructed that included statin use
(yes/no) and the variables retained in the previous steps. The analysis was then repeated using
inverse probability treatment weights (IPTW). The propensity score for each subject, defined as
the conditional probability of receiving statin therapy given in view of his/her individual covari-
ates, was estimated from a logistic regression analysis that included the same variables as those
retained for the Cox model. In the remaining analyses, patients were weighted by the inverse of
their probability of statin treatment, using stabilized weights [13].
Sensitivity analyses were used to assess the robustness of the results, by including in the
models variables that were not selected as confounders but were known to be linked to the risk
of death, such as gender, the plasma HIV-1 RNA level, and prior non-AIDS malignancies.
Results
Among 1,776 HIV-infected individuals included in the study, 138 (8%) were statin users. The
use of statins rose from 3% in 2000–2001 to 13% in 2008–2009. The most frequently prescribed
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statins were pravastatin (56%), rosuvastatin (32%) and atorvastatin (8%). The characteristics of
statin users and non users were presented in Table 1. Patients who were prescribed statins were
older (p<0.0001), more likely to have hypertension (p< 0.0001), diabetes (p< 0.0001) and
chronic renal failure (p< 0.0001), and more likely to be men who had sex with men
(p = 0.0029). They were less likely to have HCV coinfection (p = 0.0025), had a lower CD4 T
cell nadir (p = 0.0155), and were more likely to have viral load below 50 copies/mL
(p = 0.0004). Current smokers accounted for 38% of statin users and 43% of non users
(p = 0.1341). Statin users were less likely to have a BMI below 21 kg/m2 (p = 0.0548).
Seventy-six deaths occurred during a median follow-up of 53 months, including 6 deaths
among statin users. The Kaplan-Meier estimate of 7-year mortality was slightly higher, but not
significantly, among statin users than among non users (11% versus 7%, Log Rank p = 0.6335).
The following confounders were retained: age (per 10-year increment), HIV transmission
group (men who had sex with men versus all other patients), current CD4 T cell count (after
log2 transformation), haemoglobin level (after log2 transformation), BMI (<21, 21–26,27
kg/m2), smoking status (never, ceased3 years, ceased>3 years, current), anti-HCV antibod-
ies positivity (yes/no), HBs antigen positivity (yes/no), diabetes (yes/no) and hypertension
(yes/no). After weighting and stabilization, the standardized differences between statin users
and non users were less than 10% for all the above confounders showing that all non-con-
founders were well balanced in weighed analyses (Fig 1).
Association of statin use with the risk of death is depicted in Fig 2. In the univariable model,
statin use was associated with an increased risk of death (crude hazard ratio [HR] 1.22), but the
association did not reach statistical significance (95%CI 0.53–2.82). After accounting for con-
founders in the adjusted Cox model, the HR fell to 0.86 (95%CI 0.34–2.19). A similar result
was obtained with IPTW (HR 0.83, 95%CI 0.51–1.35). In the sensitivity analysis including two
IDM cases receiving statin together with the 1,776 controls ten times, the combined HR was
estimated as 0.86 (95%CI 0.66–1.13). Similar results were also obtained in the sensitivity analy-
sis including in the model variables that were not selected as confounders but were known to
be linked to the risk of death.
Discussion
Although the risk of death was higher among statin users than non users in univariable analy-
sis, with a hazard ratio of 1.22 (95%CI = 0.53–2.82), the estimated HR in the adjusted analysis
was 0.86 (95%CI = 0.34–2.19), a value similar to that of the general population in the Cochrane
meta-analysis [5].
In our study, statins had been prescribed to individuals with an elevated risk of cardiovascu-
lar disease and death as illustrated by a higher prevalence of diabetes, hypertension and smok-
ing. Statin use was defined at a fixed time point, the index date. This is a limitation of our
study. However, in a setting of free healthcare cost, statin prescription is unlikely to be inter-
rupted in patients at risk. In univariable analysis one would expect to find a higher risk of
death among patients treated with statins. When this is not the case [7,8], it points to possible
differences in medical coverage or socio-economic status between statin users and non users,
and these factors should be taken into account in the analyses. It is also important to take all
other confounders into account, while variables that might be affected by statin use, such as
cholesterol values on statin therapy, should not. Our results are similar to those of Rasmussen
et al. [9] and Overton et al. [8]. In contrast, Drechsler et al. [7] found no effect, with a HR of
0.96 (95%CI = 0.92–0.98), while Moore et al. [6] found a very strong effect with a relative haz-
ard of 0.33 (95%CI = 0.14–0.76). However, Drechsler et al. did not found an increased risk of
death in univariable analysis, suggesting difference in access to care among statin users and
Statins and All-Cause Mortality in HIV-Infected Individuals
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non-users and they adjusted for the updated LDL-cholesterol level in the multivariable models
[7] contrary to the fact that one should not adjust on the consequence of treatment when evalu-
ating treatment effect in an observational setting. Moore et al. did not take into account health-
care coverage or other important confounders such as smoking, hypertension and diabetes.
Moore's results were “to good to be true” suggesting remaining confounding, and therefore





P value of univariate conditional logistic
regression
Sex, male 125 (90.6) 1454 (88.8) <0.0001
Age, years 53 ± 10 48 ± 10 <0.0001
Follow-up time, months 48.8 (30.1–73.4) 54.4 (30.8–84.0) -
HIV transmission group, MSM 80 (58.0) 734 (44.8) 0.0029
Risk factors for cardiovascular disease
BMI
BMI < 21 kg/m2 24 (17.7) 430 (26.3)
21 kg/m2  BMI < 27 kg/m2 95 (68.7) 972 (59.3) 0.0548
BMI  27 kg/m2 19 (13.6) 236 (14.4)
Smoking
Current smoker, yes (missing for 17 statins users & 173
non-users)
48 (38.3) 699 (42.7)
Smoking cessation < 3 years 3 (2.3) 91 (5.5) 0.1341*
Smoking cessation  3 years 14 (10.5) 142 (8.7)
Hypertension or antihypertensive treatment, yes (missing
for 6 non-users)
41 (29.7) 203 (12.4) <0.0001*
Diabetes or antidiabetic treatment, yes 30 (21.7) 149 (9.1) <0.0001
Pulmonary embolism, yes 1 (0.7) 16 (1.0) 0.7702
Hepatic insufﬁciency, yes 1 (0.7) 16 (1.0) 0.7702
Chronic renal failure, yes 5 (3.6) 7 (0.4) <0.0001
Cirrhosis, yes 1 (0.7) 28 (1.7) 0.3807
Non AIDS malignancy, yes 6 (4.4) 62 (3.8) 0.7408
Haemoglobin rate, g/dL (missing for 30 statins users & 452
non-users)
14.5 (13.3–15.5) 14.3 (13.3–15.1) 0.4428
Anti-HCV antibodies, yes (missing for 10 statins users & 88
non-users)
6 (4.5) 260 (15.9) 0.0025*
HBs antigen, yes 9 (6.3) 127 (7.8) 0.5540
Characteristics of HIV infection
Plasma HIV-1 RNA† < 50 copies/mL 73 (52.9) 615 (37.6) 0.0004
CD4 T-cell nadir, cells/mm3 (missing for 1 statins user) 139 (46–248) 179 (74–301) <0.0001*
CD4 T-cell count †, cells/mm3 491 (358–656) 466 (312–656) 0.2316
CD8 T-cell count †, cells/mm3 (missing for 2 statins users &
29 non-users)
900 (368–1194) 895 (620–1225) 0.9894
CD4/CD8 T-cell ratio † (missing for 3 statins users & 29
non-users)
0.6 (0.4–0.8) 0.5 (0.3–0.8) 0.1012
AIDS prior to the index date 49 (35.5) 476 (29.1) 0.1109
Table entries are n (%), mean ± standard deviation, or median (interquartile range), as appropriate.
Index date: date of MI diagnosis.
MSM: men having sex with men, BMI: body mass index, AIDS: acquired immune deﬁciency syndrome, HCV: hepatitis C virus, HBs: hepatitis B surface.
* p values were calculated including missing data.
† Within three months prior to the index date.
doi:10.1371/journal.pone.0133358.t001
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unlikely to reflect a causal relationship [14]. Although our findings, like those of Rasmussen
and Overton [8,9], are more likely to estimate the true effect of statin use on the risk of death
among HIV-infected individuals, an effect similar to that in the general population, all three
studies lacked sufficient power to show a statistically significant effect.
Conclusion
The effect of statins on all-cause mortality appears to be similar in HIV-infected and-unin-
fected populations. The potential benefits of statin therapy in HIV-infected patients should be
Fig 1. Standardized difference between statin users and non users. Abbreviations: BMI = body mass index, HCV = hepatitis C virus, HBs = hepatitis B,
AIDS = acquired immune deficiency syndrome.
doi:10.1371/journal.pone.0133358.g001
Fig 2. Association between statin use and the risk of death among HIV-infected individuals.
Adjustment for gender, HIV transmission group, age, CD4 T cell count, plasma HIV-1 RNA, anti-HCV
antibodies and Hbs antigen status, BMI, haemoglobin, smoking, hypertension and diabetes. Abbreviations:
HR = hazard ratio, IPTW = inverse probability of treatment weighting.
doi:10.1371/journal.pone.0133358.g002
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weighed up in view of the risk of drug-drug interactions and known adverse effects such as the
increased risk of diabetes and myopathy [15].
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Viget), Corevih PACA Est (Nice Hôpital Archet 1: PM Roger, C Pradier, P Pugliese, E
Rosenthal, J Durant, E Cua, A Naqvi, I Perbost, K Risso; CH Antibes-Juan les Pins: D Quin-
sat; CHI de Fréjus/St Raphaël: P Del Giudice; CH de Grasse: PY Dides), Corevih PACA
Ouest (Marseille Hôpital de la Conception: P Enel, R Sambuc, MS Antolini-Bouvenot, P
Druart, L Meddeb, I Ravaux, H Tissot-Dupont, A Menard, C Tomei, C Dhiver; Marseille
Hôpital Nord: S Mokhtari, J Moreau, MJ Soavi, V Thomas; Marseille Hôpital Sainte-Margue-
rite: I Poizot-Martin, S Bregigeon, O Faucher, V Obry-Roguet, AS Ritleng, N Petit; Marseille
Centre pénitentiaire des Baumettes: C Bartoli, JM Ruiz, D Blanc; CH d’Aix-En-Provence: T
Allegre, M Sordage, JM Riou, C Faudon; CH d’Avignon: B Slama, H Zerazhi, O Boulat, S
Chebrek, M Beyrne; CH de Digne Les Bains: P Granet Brunello; CH de Gap: L Pellissier, D
Bonnabel; CH de Martigues: R Cohen Valensi, B Mouchet, G Mboungou; CHI de Toulon: A
Lafeuillade, E Hope-Rapp, G Hittinger, G Philip, V Lambry), Corevih Pays de la Loire
(CHU de Nantes: E Billaud, F Raffi, C Allavena, N Hall, S Pineau), Corevih de la Vallée du
Rhône (Lyon Hôpital de la Croix-Rousse: C Chidiac, L Cotte, T Ferry, T Perpoint, P Miailhes;
Lyon Hôpital Edouard Herriot: JM Livrozet, A Boibieux, D Makhloufi, F Brunel, P Chiar-
ello).
Overseas: Corevih Guadeloupe (CHU de Pointe-à-Pitre: B Hoen, I Lamaury, I Fabre, K
Samar, E Duvallon; CH Saint-Martin: C Clavel, S Stegmann, VWalter), Corevih Guyane
(CH de Cayenne: M Nacher, L Adriouch, F Huber, V Vanticlke, P Couppié), Corevih Marti-
nique (CHU de Fort-de-France: A Cabié, S Abel, S Pierre-François), Corevih de La Réunion
(CHU Félix Guyon: C Gaud, C Ricaud, R Rodet, G Wartel, C Sautron; GH Sud Réunion: P
Poubeau, G Borgherini, G Camuset).
The full list of FHDH-ANRS CO4 investigators can be found at http://www.ccde.fr.
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